0001493152-23-028716.txt : 20230814
0001493152-23-028716.hdr.sgml : 20230814
20230814190730
ACCESSION NUMBER: 0001493152-23-028716
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230811
FILED AS OF DATE: 20230814
DATE AS OF CHANGE: 20230814
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morris Jeffrey Allen
CENTRAL INDEX KEY: 0001959175
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36457
FILM NUMBER: 231172717
MAIL ADDRESS:
STREET 1: 1729 TRIANGLE PARK DR.
CITY: MARYVILLE
STATE: TN
ZIP: 37801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000315545
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900031917
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
BUSINESS PHONE: (866) 594-5999
MAIL ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
FORMER COMPANY:
FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020417
FORMER COMPANY:
FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC
DATE OF NAME CHANGE: 20011126
FORMER COMPANY:
FORMER CONFORMED NAME: SPM GROUP INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0508
4
2023-08-11
0
0000315545
PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT
0001959175
Morris Jeffrey Allen
1729 TRIANGLE PARK DRIVE
MARYVILLE
TN
37801
0
0
1
0
0
Common Stock
12000000
D
Common Stock
6500000
I
By IRA
Series D-1 Convertible Preferred Stock
3995747
D
8% Secured Convertible Promissory Note
2.862
2023-08-11
4
A
0
700000
0
A
2023-08-11
2024-08-11
Series D-1 Convertible Preferred Stock
244584
244584
D
The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock.
The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan.
The reporting person has sole voting and dispositive power over 3,995,747 shares of Series D-1 Convertible Preferred Stock, convertible into 39,957,470 shares of Common Stock.
The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
/s/ Jeffrey Allen Morris
2023-08-14